⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL28007867 | 0.94 | LMNA (0.56) | — | |
| Glycerin SCHEMBL8102676 | 0.86 | LMNA (0.64) | — | |
| Glycerin SCHEMBL9770227 | 0.83 | LMNA (0.60) | — | |
| Glycerin SCHEMBL9770368 | 0.83 | LMNA (0.60) | — | |
| Glycerin SCHEMBL4330923 | 0.83 | LMNA (0.60) | — | |
| Glycerin SCHEMBL569689 | 0.83 | LMNA (0.60) | — | |
| Glycerin SCHEMBL13279055 | 0.83 | LMNA (0.60) | — | |
| Glycerin SCHEMBL10475823 | 0.83 | LMNA (0.60) | — | |
| Glycerin SCHEMBL2674761 | 0.83 | LMNA (0.60) | — | |
| Glycerin SCHEMBL343633 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0249587-B1 | SOLID PHARMACEUTICAL PREPARATION WITH EXTENDED RELEASE AND PROCESS FOR ITS PREPARATION | Aktiebolaget Hässle (SE) | 1992-05-20 | — | — | EP | claimed |
| CN-112725455-B | Application of m6A key gene and risk model in prediction of prognosis of adrenocortical adenocarcinoma | 中南大学湘雅三医院 | 2022-06-07 | — | — | CN | disclosed |
| CN-112725455-A | Application of m6A key gene and risk model in prediction of prognosis of adrenocortical adenocarcinoma | 中南大学湘雅三医院 | 2021-04-30 | — | — | CN | disclosed |
| EP-3320914-B1 | T-HELPER 1 ADJUVANT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | YEDA RES AND DEVELOPMENT CO LTD AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) | 2020-12-30 | — | — | EP | disclosed |
| US-20190022198-A1 | Individualized Immunomodulation Therapy for Neurodegenerative Disorders, CNS Injury and Age-Related Dementia | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-01-24 | — | — | US | disclosed |
| US-20180371416-A1 | SCAFFOLD-FREE TISSUE CONSTRUCTS | UNIV CASE WESTERN RESERVE (US) | 2018-12-27 | — | — | US | disclosed |
| US-10030228-B2 | Scaffold-free tissue constructs | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-07-24 | — | — | US | disclosed |
| EP-3320914-A1 | T-HELPER 1 ADJUVANT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science (IL) | 2018-05-16 | — | — | EP | disclosed |
| CN-107474265-A | A kind of preparation method of polyvinyl alcohol conductive hydrogel | 福州大学 | 2017-12-15 | — | — | CN | disclosed |
| US-20150238582-A1 | INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE DISORDERS, CNS INJURY AND AGE-RELATED DEMENTIA | YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) | 2015-08-27 | — | — | US | disclosed |
| EP-1572724-A2 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | Dyax Corp. (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1563059-A1 | METHODS, NUCLEIC ACID CONSTRUCTS AND CELLS FOR TREATING NEURODEGENERATIVE DISORDERS | Ramot at Tel Aviv University Ltd. (IL) | 2005-08-17 | — | — | EP | disclosed |
| US-20040197832-A1 | Immunohistochemical staining, use of human leukocyte antigen specific antibody and fluorescence in situ hybridization for determining fetal gender and/or chromosomal aneuploidy | MOR RESEARCH APPLICATIONS LTD. (IL) | 2004-10-07 | — | — | US | disclosed |
| WO-2004046348-A1 | METHODS, NUCLEIC ACID CONSTRUCTS AND CELLS FOR TREATING NEURODEGENERATIVE DISORDERS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2004-06-03 | — | — | WO | disclosed |
| WO-2003074005-A2 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-0866969-B1 | METHOD OF CANCER DETECTION | IMMUNA CARE CORP (US) | 2002-12-04 | — | — | EP | disclosed |
| US-5962242-A | NONINVASIVE DIAGNOSTIC METHOD BY DETECTING THE LEVEL OF A PARTICULAR METABOLITE OF ESTRONE AND ITS RESPECTIVE 3-GLUCURONIDE FROM SAMPLE OF URINE, SERUM OR TISSUE; COMPARING TO HEALTHY HUMANS | IMMUNA CARE CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
| US-5854009-A | Method of detecting estrogen-sensitive pathologies | IMMUNA CARE CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0866969-A1 | METHOD OF CANCER DETECTION | IMMUNA CARE CORPORATION (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997011374-A1 | METHOD OF CANCER DETECTION | IMMUNA CARE CORPORATION (US) | 1997-03-27 | — | — | WO | disclosed |